<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035904</url>
  </required_header>
  <id_info>
    <org_study_id>2011-006331-35</org_study_id>
    <nct_id>NCT02035904</nct_id>
  </id_info>
  <brief_title>Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate efficacy and safety of long term (14 days) wound infusion&#xD;
      with levobupivacaine in patients with breast cancer undergoing mastectomy with immediate&#xD;
      breast reconstruction: this is a double blind, randomized, parallel group study. The study&#xD;
      moves from the concept that nociceptive stimulus last further than 48 hours after surgical&#xD;
      intervention: long term analgesia is necessary to provide a real benefit to the patient and&#xD;
      provide central sensitization. Intralesional catheter is placed at the end of surgery. In the&#xD;
      first 24 postoperative hours we provide continuous wound infusion with levobupivacaine 0,25%&#xD;
      5ml/h with morphine Patient Controlled Analgesia (PCA) when NRS &gt;4. From the second&#xD;
      postoperative day morphine PCA is removed and patients are randomized to receive&#xD;
      levobupivacaine 0,25% or saline, released with 5 ml boluses and lock-out of 2 hours, with&#xD;
      rescue analgesia with tramadol 37,5 mg + acetaminophen 325 mg oral fix combination (Patrol).&#xD;
      Intralesional catheter is taken off 14 days after surgical intervention or after 36 hours of&#xD;
      non-use.&#xD;
&#xD;
      Pain evaluation (NRS at rest and movement) and oral rescue doses consumption are performed;&#xD;
      pain physicians also care about any catheter-related or drug-related side effect, registering&#xD;
      number of total boluses. Patients are provided with a home diary for pain scores to be filled&#xD;
      and brought back when surgical visit is performed. A phone interview at 1 and 3 month is&#xD;
      performed to investigate pain chronicization.&#xD;
&#xD;
      Surgical evaluation is provided, also to establish any catheter-related infective or healing&#xD;
      complication.&#xD;
&#xD;
      Physiatric evaluation before the intervention and 1 and 3 months is provided to ensure&#xD;
      rehabilitation process.&#xD;
&#xD;
      A validated questionnaire (short form 36/ SF-36) must be filled by all patients, to&#xD;
      understand differences in return to a normal quality of life and to social activities between&#xD;
      the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in oral Tramadol-Paracetamol combination consumption from 2nd to 14th day after mastectomy</measure>
    <time_frame>from day 2 to 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction in pain values at rest and movement in treatment group</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of drug-related side effects</measure>
    <time_frame>up to 14 days</time_frame>
    <description>local anesthetic toxicity, opioid side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of catheter-related surgical complications</measure>
    <time_frame>up to 1 month</time_frame>
    <description>infections, healing retardation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>earlier upper limb rehabilitation</measure>
    <time_frame>up to 1 month</time_frame>
    <description>physiatric evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>earlier return to social activities and good quality of life</measure>
    <time_frame>up to 1 month</time_frame>
    <description>validated SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>different chronic pain incidence</measure>
    <time_frame>up to 3 months</time_frame>
    <description>phone interview at 1 and 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Pain</condition>
  <condition>Chronic Pain</condition>
  <condition>Wound Infusion</condition>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient controlled infusion 5 ml bolus, lock out 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)</intervention_name>
    <description>patient controlled infusion from the 2nd day after surgery</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>patient controlled infusion from the 2nd day after surgery</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine continuous infusion</intervention_name>
    <description>Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intrawound infusion catheter</intervention_name>
    <description>placed by surgeon at the end surgery in all patients</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
    <description>PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patrol</intervention_name>
    <description>tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  F; age 18 to 70&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) I e II;&#xD;
&#xD;
          -  breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing&#xD;
             mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c,&#xD;
             lymphnode biopsy and axillary dissection;&#xD;
&#xD;
          -  immediate sub-pectoral prosthetic reconstruction;&#xD;
&#xD;
          -  signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  preexisting pectoral, axillar, thoracic homolateral pain&#xD;
&#xD;
          -  habitual opioid consumption;&#xD;
&#xD;
          -  drug-alcoholics addiction ;&#xD;
&#xD;
          -  ICU postoperative recovery;&#xD;
&#xD;
          -  kidney failure (creatinin &gt; 2 g/dl, creatinin &lt;clearance 30 ml/h) and/or hepatic&#xD;
             failure (cholinesterase &lt; 2000 UI);&#xD;
&#xD;
          -  cardiac arrhythmias o;&#xD;
&#xD;
          -  Epilepsy;&#xD;
&#xD;
          -  Psychiatric, cognitive disorders, mental retardation;&#xD;
&#xD;
          -  Coagulopathies (INR &gt; 2, activated partial thromboplastin time - aPTT&gt;44 sec);&#xD;
&#xD;
          -  platelet count less than 100.000/mm3;&#xD;
&#xD;
          -  BMI &gt; 30;&#xD;
&#xD;
          -  Allergies to study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allegri Massimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pain Therapy Service IRCCS Policlinico S Matteo Pavia Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allegri Massimo, MD</last_name>
    <phone>+390382502627</phone>
    <email>massimo.allegri@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesia - Pain Therapy Service</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allegri Massimo, MD</last_name>
      <phone>+390382502627</phone>
      <email>massimo.allegri@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Bugada Dario, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 11, 2014</study_first_submitted>
  <study_first_submitted_qc>January 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Massimo Allegri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

